WHWK Insider Behzad Aghazadeh Buys 38,040 Shares
Insider Behzad Aghazadeh purchased a significant number of shares in Whitehawk Therapeutics on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Behzad Aghazadeh bought 38,040 shares of Whitehawk Therapeutics, Inc. ($WHWK) on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $WHWK is up 7.2% after 1 week, down 7.7% after 1 month and down 30.5% to date (from the $4.16 close on Jun 12, 2026).
WHWK
Whitehawk Therapeutics, Inc.
Key Points
- On June 12, 2026, Behzad Aghazadeh bought 38,040 shares of Whitehawk Therapeutics, valued at about $155,000 based on the current price of $4.1 per share.
- Whitehawk Therapeutics has seen a series of insider purchases, with multiple executives acquiring the same number of shares on the same day.
- Analysts remain optimistic, with recent ratings indicating a buy and price targets reaching as high as $10.
Get $WHWK trade alerts by text
We text you when insiders, Congress or big funds trade $WHWK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Whitehawk Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
Behzad Aghazadeh purchased 38,040 shares of Whitehawk Therapeutics, Inc. (WHWK) on June 12, 2026. This acquisition is valued at approximately $155,000 based on the current share price of $4.1. Aghazadeh's buy is part of a broader trend, as several insiders made similar purchases on the same day.
Other Insiders Join In
On June 12, 2026, several other insiders also bought 38,040 shares each. Mohammad Hirmand, Baiteng Zhao, Richard Maroun, Emma Reeve, Neil Desai, and Caley Castelein all made the same purchase, indicating strong confidence in the company's future.
How Whitehawk Therapeutics, Inc. Stock Has Traded
Whitehawk Therapeutics shares are currently trading at $4.1, which is close to the midpoint of its 52-week range between $1.82 and $5.50. The stock's price reflects a recent trend of insider activity, suggesting potential bullish sentiment among the company's executives.
Analysts Set New Price Targets
Analysts are optimistic about Whitehawk Therapeutics. On June 25, 2026, B. Riley Securities initiated a buy rating with a $10 price target. Stifel also initiated coverage on October 1, 2026, with a buy rating and a $9 target, while Leerink Partners rated it outperform with a $9 target on July 13, 2026. The average price target among analysts is $7.5, with six opinions supporting a buy recommendation.
What Whitehawk Therapeutics, Inc. Does
Whitehawk Therapeutics, Inc. is a clinical-stage company focused on developing innovative cancer treatments through next-generation antibody drug conjugates. The recent insider purchases reflect a belief in the company's potential to advance its therapeutic technologies.
What’s Next for Whitehawk?
Investors should keep an eye on the upcoming earnings report scheduled for November 5, 2026. The recent insider buying activity and positive analyst ratings suggest that there's considerable interest in the company's future. Remember, the current insider transactions reflect positions as of June 12, 2026, and may not represent ongoing holdings.
Related Filing Alerts
Source: Behzad Aghazadeh's Form 4 filing on $WHWK (Jun 12, 2026). Find the original filing: WHWK Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts